Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

by · The Cerbat Gem

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Sunday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Read Our Latest Stock Report on SUPN

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $32.28 on Friday. The firm has a market cap of $1.80 billion, a P/E ratio of 30.17 and a beta of 0.83. The stock has a 50 day simple moving average of $36.02 and a two-hundred day simple moving average of $35.13. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth $25,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $42,000. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $52,000. Finally, Headlands Technologies LLC raised its holdings in Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares in the last quarter.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Further Reading